Current Cardiology Reports

, 16:493

Cangrelor: Review of the Drug and the CHAMPION Programme (Including PHOENIX)

New Therapies for Cardiovascular Disease (KW Mahaffey, Section Editor)

DOI: 10.1007/s11886-014-0493-4

Cite this article as:
Marino, M., Rizzotti, D. & Leonardi, S. Curr Cardiol Rep (2014) 16: 493. doi:10.1007/s11886-014-0493-4
Part of the following topical collections:
  1. Topical Collection on New Therapies for Cardiovascular Disease

Abstract

Platelet inhibition is the main goal of ancillary pharmacologic therapy during percutaneous coronary interventions (PCI). Thienopyridines and ticagrelor are oral drugs developed for this purpose. Cangrelor is an intravenous, non-thienopyridine antagonist of the P2Y12 receptor with a rapid, potent, predictable, and quickly reversible effect. Cangrelor has been studied in a broad population intended to receive PCI in the CHAMPION program, where it was compared with different clopidogrel regimens. The first two trials, CHAMPION PCI and PLATFORM, failed their primary objective, likely for challenges in the adjudication of PCI-related myocardial infarction. In a third trial that implemented the universal definition of MI, CHAMPION PHOENIX, a reduction of thrombotic events, including stent thrombosis, was observed. In the BRIDGE trial cangrelor has been studied in patients who had to prematurely interrupt antiplatelet therapy for surgery. Cangrelor appears a promising agent in patients who require PCI or when a rapid reversal is needed.

Keywords

CangrelorPercutaneous coronary interventionsPlatelet inhibitionAcute coronary syndromeCHAMPION Programme

Clinical Trial Acronyms

CHAMPION PCI

Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition PCI

CHAMPION PLATFORM

Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition PLATFORM

CHAMPION PHOENIX

Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition PHOENIX

BRIDGE

Maintenance of Platelet inihiBition With cangRelor After dIscontinuation of ThienopyriDines in Patients Undergoing surGEry

GUSTO

Global Utilization of Streptokinase and Tissue plasminogen activator in Occluded arteries

ACUITY

Acute Catheterization and Urgent Intervention Triage StrategY

TIMI

Thrombolysis in Myocardial Infarction

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Marcello Marino
    • 1
  • Diego Rizzotti
    • 2
  • Sergio Leonardi
    • 2
  1. 1.University of PaviaPaviaItaly
  2. 2.Fondazione IRCCS Policlinico San MatteoPaviaItaly